Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD.
Authors
Senkus-Konefka, EDomchek, S
Im, S
Xu, B
Armstrong, Anne C
Masuda, N
Delaloge, S
Li, W
Tung, N
Conte, P
Wu, W
Goessl, C
Runswick, S
Robson, M
Affiliation
Medical Academy of Gdansk, Oncology and Radiotherapy, Gdansk Wreszcz, PolandIssue Date
2018-04
Metadata
Show full item recordCitation
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. 2018, 92:.S19 Eur J CancerJournal
European Journal of CancerDOI
10.1016/S0959-8049(18)30285-5Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S0959804918302855Type
Meetings and ProceedingsLanguage
enISSN
09598049ae974a485f413a2113503eed53cd6c53
10.1016/S0959-8049(18)30285-5